1-3 of 3
Shraddha Desai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subcutaneous Marzeptacog Alfa (Activated) Versus Intravenous rFVIIa for Treatment of Episodic Bleeding in FVIII Deficient Hemophilia a Rats

Tom Knudsen, Peter Johansen, Jill Reckless, Shraddha Desai, Grant E. Blouse
Journal: Blood
Blood (2021) 138 (Supplement 1): 3181.
https://doi.org/10.1182/blood-2021-151284
Published: 2021
Journal Articles

The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptocog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with Inhibitors

Linda Neuman, MD, Shraddha Desai, PhD MS, Tom Knudsen, PhD DVM, Frank Del Greco, MBA, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-137806
Published: 2020
Journal Articles

Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (activated) in the Treatment of Episodic Bleeding in Subjects with Inherited Bleeding Disorders

Linda Neuman, MD, Shraddha Desai, PhD MS, Frank Del Greco, MBA, Tom Knudsen, PhD DVM, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-137223
Published: 2020